Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A2102 + adebrelimab + SHR-8068
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is an **experimental combination regimen** consisting of SHR-A2102, adebrelimab, and SHR-8068, currently under evaluation in clinical trials for advanced or metastatic non-small cell lung cancer (NSCLC). Adebrelimab is a fully humanized IgG4 monoclonal antibody that blocks PD-L1, disrupting PD-L1/PD-1 immune checkpoint signaling and thus restoring anti-tumor T-cell function[2][4]. SHR-A2102 and SHR-8068 are novel compounds, presumed to be next-generation targeted therapies or immunomodulatory agents, but no detailed mechanism-of-action or molecular profile is available in public clinical trial registries or literature for SHR-A2102 or SHR-8068 as of September 2025[1][3]. The combination represents an immunotherapy-based strategy with potential for synergistic anti-tumor effects in hard-to-treat populations, currently being studied primarily in China.
- Brand names
- AreliliAriely
- Other names
- SHR-A2102SHR-A-2102SHR-A 2102SHR 8068SHR8068SHR-8068
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on SHR-A2102 + adebrelimab + SHR-8068.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A2102 + adebrelimab + SHR-8068.